Mending the Heart: The Edwards Lifesciences Story

Discover how a retired fuel pump engineer and a young surgeon revolutionized cardiac care, moving heart surgery from the saw to the catheter.[INTRO]ALEX: In 1960, a surgeon named Albert Starr placed a small, caged metal ball into a human heart, hoping it would act as a valve. It worked, and that single device didn't just save a patient; it birthed a multi-billion dollar industry.JORDAN: Wait, a metal ball? We’re talking about the thing that keeps you alive being replaced by hardware from a machine shop?ALEX: Exactly. That device was the Starr-Edwards valve, the foundation of what we now know as Edwards Lifesciences, a company that has spent the last sixty years moving heart surgery from the bone-saw to the high-tech catheter.JORDAN: So, they basically turned open-heart surgery into a 'plug-and-play' procedure? I need to know how they pulled that off.[CHAPTER 1 - Origin]ALEX: It all starts with a guy named Miles “Lowell” Edwards. He was a 60-year-old retired engineer with sixty patents for things like fuel pumps and aircraft parts, but he wanted to do something that actually felt meaningful.JORDAN: Most retirees take up golf. This guy decides to fix the human circulatory system?ALEX: Pretty much. In 1958, he met Dr. Albert Starr, a young surgeon who was tired of watching patients die because their heart valves were failing. Starr told Edwards, "I need an artificial heart."JORDAN: That is a massive ask for a guy who used to build fuel pumps.ALEX: Edwards actually talked him down. He said a whole heart was too complex, so they should start with just the valves. They spent two years in a lab figuring out how to make something that wouldn't be rejected by the body and could beat 100,000 times a day without breaking.JORDAN: That’s a lot of pressure. If that valve fails, there’s no Plan B.ALEX: Right. They settled on a "caged-ball" design—a silicone ball inside a cobalt-chromium cage. On September 21, 1960, they successfully put it in a patient, and suddenly, the impossible was possible.[CHAPTER 2 - Core Story]ALEX: After that success, Edwards Laboratories grew fast. They were bought by bigger companies like Baxter International, but in the year 2000, they spun off to become an independent company again, led by a CEO named Mike Mussallem.JORDAN: Why go independent? Weren’t they doing fine as part of a giant conglomerate?ALEX: Mussallem wanted the freedom to take a massive gamble. He saw a huge group of patients—mostly the elderly and frail—who had failing aortic valves but were too weak to survive open-heart surgery.JORDAN: So they were just left to die because the "cure" was too dangerous?ALEX: Exactly. Edwards decided to bet the entire company on a technology called TAVR—Transcatheter Aortic Valve Replacement. The goal was to fold a heart valve up into a tiny tube, thread it through an artery in the leg, and pop it open inside the heart.JORDAN: That sounds like building a ship inside a bottle, but the bottle is a living person.ALEX: It was incredibly risky. They spent years on the PARTNER trials, which were these massive clinical studies to prove it was safe. In 2011, the FDA finally gave them the green light.JORDAN: I bet the traditional surgeons weren't happy about cardiologists doing "surgery" through a leg artery.ALEX: There was a absolute turf war at first. Surgeons felt like their territory was being invaded, but the results were so good they couldn't ignore them. Eventually, it forced the creation of the "Heart Team"—where surgeons and cardiologists actually sit down and decide together what’s best for the patient.[CHAPTER 3 - Why It Matters]ALEX: Today, Edwards Lifesciences is the dominant force in structural heart tech. Their SAPIEN valve, which is made from cow heart tissue on a metal frame, is the gold standard for TAVR.JORDAN: Is it still just for the people who are too weak for regular surgery?ALEX: Not anymore. By 2019, they got approval to use it on "low-risk" patients—basically anyone who wants to avoid having their chest cracked open. They’ve moved from being a niche solution to redefining how we treat heart disease globally.JORDAN: And I'm guessing they aren't stopping at the aortic valve?ALEX: No, they’re currently chasing the "mitral frontier." The mitral and tricuspid valves are way more complex to fix than the aortic one, and Edwards is spending about 18% of its revenue on R&D to figure it out. They’re even using AI now to predict when a patient’s blood pressure is about to drop before it actually happens.JORDAN: So they’ve gone from mechanical fuel pumps to predictive AI heart monitors.ALEX: It’s a complete evolution. They’ve even moved their manufacturing all over the world, from Singapore to a brand new high-tech facility in Ireland, just to keep up with the demand for these valves.[OUTRO]JORDAN: This is a wild jump from a 60-year-old guy in a garage. What’s the one thing to remember about Edwards Lifesciences?ALEX: They are the company that turned the most invasive surgery in medicine into a procedure you can often go home from the very next day.JORDAN: That’s amazing. That's Wikipodia — every story, on demand. Search your next topic at wikipodia.ai